Investigational drug · Phase 2
Unasnemab
Also called: MT-3921
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Spinal Cord Injury.
Phase 2Last checked: Nov 20, 2026Latest source record: Dec 16, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "Unasnemab"
First trial start
2021
Aug 27, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Unasnemab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Spinal Cord Injury
Largest trials
Live from ClinicalTrials.gov: studies naming "Unasnemab" as an intervention, largest first.
Tanabe Pharma America, Inc.Industry
NCT04683848 · 72 participants · Start Aug 27, 2021 · Primary completion Dec 24, 2024
Drug: MT-3921; Placebo · For: Spinal Cord Injury
Sites: Orange, California; Tallahassee, Florida; Augusta, Georgia · 23 sites in all
- A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM)Completed
Tanabe Pharma CorporationIndustry
NCT05240612 · 15 participants · Start May 2, 2022 · Primary completion Sep 14, 2023
Drug: MT-3921; Placebo · For: HTLV-1-Associated Myelopathy (HAM)
Sites: Kawasaki-shi, Japan
Tanabe Pharma CorporationIndustry
NCT05396235 · 10 participants · Start Aug 3, 2022 · Primary completion Dec 24, 2022
Drug: MT-3921; Placebo · For: Healthy Adult Males
Sites: Shinjuku-ku, Japan
Newest research
PubMed records naming it or its code names, newest first.
- Virus-induced RGMa expression drives neurodegeneration in HTLV-1-associated myelopathy.
Araya N, Yamagishi M, Nakashima M, et al. · JCI Insight 2025
Also in development for Spinal Cord Injury
- iPSChuman allogeneic induced pluripotent stem cell -derived dopaminergic neural progenitor cell, Allogeneic Human Induced Pluripotent Stem Cell -Derived Motor Neuron Progenitor CellsPhase 23 trials
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. · Spinal Cord Injury, Safety, Efficacy
- EG110APhase 22 trials
Cyllene Therapeutics · Neurogenic Detrusor Overactivity, Spinal Cord Injuries, Urinary Bladder, Overactive
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.